Global Neurocognitive Disorder Treatment Market: Competitive Landscape
The key players in global neurocognitive disorder treatment market are focusing on developing innovative, new, and efficient neurocognitive disorder treatment drugs that are launched in the market to meet the demand from consumers for various types of neurocognitive disorder treatments. For instance, in March 2018, Biogen announced to enter into an agreement to acquire Pfizer Inc. phase 2b ready AMPA receptor potentiator for cognitive impairment.
Furthermore, in May 2019, T3D therapeutics received grant of US$ 9 million from National Institute on Aging (NIA) to develop drug T3D-959 for neurocognitive disease.
Key players operating in the global neurocognitive disorder treatment market include A B Science, Abbive, A C immune, Biogen, Eisai, Immunobrain, Mediti Pharma Inc., Ono Pharmaceuticals, Proclar Biosciences, Problodrug AG, Roche, T3D Therapeutics, and Purdue Pharma.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients